Today Curis Incorporated (NASDAQ:CRIS) Reported Decrease in Shorted Shares

November 21, 2017 - By Jacob Falcon

 Today Curis Incorporated (NASDAQ:CRIS) Reported Decrease in Shorted Shares

Investors sentiment increased to 1.52 in Q2 2017. Its up 0.15, from 1.37 in 2017Q1. It increased, as 9 investors sold Curis, Inc. shares while 20 reduced holdings. 14 funds opened positions while 30 raised stakes. 72.75 million shares or 0.77% less from 73.32 million shares in 2017Q1 were reported.
Meridian Inv Counsel invested in 0.01% or 10,000 shares. Tiaa Cref Mgmt Limited Liability stated it has 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Glenmede Tru Na stated it has 0% in Curis, Inc. (NASDAQ:CRIS). Creative Planning holds 0% or 28,000 shares in its portfolio. Rhumbline Advisers owns 127,529 shares for 0% of their portfolio. Sg Americas Securities Lc holds 0% or 35,971 shares in its portfolio. Proshare Advisors Limited Liability Corporation has invested 0% in Curis, Inc. (NASDAQ:CRIS). The New York-based American Group Inc Incorporated has invested 0% in Curis, Inc. (NASDAQ:CRIS). Renaissance Tech Ltd Liability reported 261,700 shares. State Street Corp owns 1.86M shares. Strs Ohio invested 0% in Curis, Inc. (NASDAQ:CRIS). New York State Common Retirement Fund holds 0% or 101,500 shares in its portfolio. First Eagle Inv has 0.11% invested in Curis, Inc. (NASDAQ:CRIS). Financial Bank Of America Corporation De invested in 22,525 shares or 0% of the stock. Deutsche Commercial Bank Ag has invested 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS).

The stock of Curis Incorporated (NASDAQ:CRIS) registered a decrease of 3.91% in short interest. CRIS’s total short interest was 1.87 million shares in November as published by FINRA. Its down 3.91% from 1.94 million shares, reported previously. With 704,900 shares average volume, it will take short sellers 3 days to cover their CRIS’s short positions. The short interest to Curis Incorporated’s float is 1.65%.

About 505,370 shares traded. Curis, Inc. (NASDAQ:CRIS) has risen 2.47% since November 21, 2016 and is uptrending. It has underperformed by 14.23% the S&P500.

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The company has market cap of $147.49 million. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase (PI3K) enzymes. It currently has negative earnings. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Among 5 analysts covering Curis (NASDAQ:CRIS), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Curis had 7 analyst reports since August 10, 2015 according to SRatingsIntel. On Monday, September 21 the stock rating was downgraded by Zacks to “Sell”. The firm has “Buy” rating given on Monday, October 23 by Guggenheim. The firm has “Hold” rating given on Tuesday, September 1 by Zacks. The firm earned “Buy” rating on Monday, November 9 by TH Capital. The company was initiated on Tuesday, August 11 by FBR Capital. The stock of Curis, Inc. (NASDAQ:CRIS) earned “Buy” rating by Roth Capital on Monday, November 9.

Another recent and important Curis, Inc. (NASDAQ:CRIS) news was published by Globenewswire.com which published an article titled: “Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call …” on November 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.